Medical Care

Global Cholangiocarcinoma Pipeline Market Research Report 2025

The global market for Cholangiocarcinoma Pipeline was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Cholangiocarcinoma Pipeline, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cholangiocarcinoma Pipeline.
The Cholangiocarcinoma Pipeline market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cholangiocarcinoma Pipeline market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cholangiocarcinoma Pipeline companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Medivir
Hutchison Medipharma
Agios Pharmaceuticals
TransThera Biosciences
Senhwa Biosciences
Eisai
EMD Serono
Taiho Oncology
Sirnaomics
RedHill Biopharma
MacroGenics
Chia Tai Tianqing Pharmaceutical Group
Sirtex Medical
Delcath Systems Inc.
Innovent Biologics
PCI Biotech AS
Basilea Pharmaceutica
QED Therapeutics
Bristol-Myers Squibb
AstraZeneca
Eli Lilly and Company
Toray Industries
Bold Therapeutics
Segment by Type
Mono
Combination
Segment by Application
Gene Therapy
Stem Cell Therapy
Gene Therapy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cholangiocarcinoma Pipeline company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cholangiocarcinoma Pipeline Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Mono
1.2.3 Combination
1.3 Market by Application
1.3.1 Global Cholangiocarcinoma Pipeline Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Gene Therapy
1.3.3 Stem Cell Therapy
1.3.4 Gene Therapy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cholangiocarcinoma Pipeline Market Perspective (2020-2031)
2.2 Global Cholangiocarcinoma Pipeline Growth Trends by Region
2.2.1 Global Cholangiocarcinoma Pipeline Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Cholangiocarcinoma Pipeline Historic Market Size by Region (2020-2025)
2.2.3 Cholangiocarcinoma Pipeline Forecasted Market Size by Region (2026-2031)
2.3 Cholangiocarcinoma Pipeline Market Dynamics
2.3.1 Cholangiocarcinoma Pipeline Industry Trends
2.3.2 Cholangiocarcinoma Pipeline Market Drivers
2.3.3 Cholangiocarcinoma Pipeline Market Challenges
2.3.4 Cholangiocarcinoma Pipeline Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cholangiocarcinoma Pipeline Players by Revenue
3.1.1 Global Top Cholangiocarcinoma Pipeline Players by Revenue (2020-2025)
3.1.2 Global Cholangiocarcinoma Pipeline Revenue Market Share by Players (2020-2025)
3.2 Global Cholangiocarcinoma Pipeline Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Cholangiocarcinoma Pipeline Revenue
3.4 Global Cholangiocarcinoma Pipeline Market Concentration Ratio
3.4.1 Global Cholangiocarcinoma Pipeline Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cholangiocarcinoma Pipeline Revenue in 2024
3.5 Global Key Players of Cholangiocarcinoma Pipeline Head office and Area Served
3.6 Global Key Players of Cholangiocarcinoma Pipeline, Product and Application
3.7 Global Key Players of Cholangiocarcinoma Pipeline, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cholangiocarcinoma Pipeline Breakdown Data by Type
4.1 Global Cholangiocarcinoma Pipeline Historic Market Size by Type (2020-2025)
4.2 Global Cholangiocarcinoma Pipeline Forecasted Market Size by Type (2026-2031)
5 Cholangiocarcinoma Pipeline Breakdown Data by Application
5.1 Global Cholangiocarcinoma Pipeline Historic Market Size by Application (2020-2025)
5.2 Global Cholangiocarcinoma Pipeline Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Cholangiocarcinoma Pipeline Market Size (2020-2031)
6.2 North America Cholangiocarcinoma Pipeline Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Cholangiocarcinoma Pipeline Market Size by Country (2020-2025)
6.4 North America Cholangiocarcinoma Pipeline Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cholangiocarcinoma Pipeline Market Size (2020-2031)
7.2 Europe Cholangiocarcinoma Pipeline Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Cholangiocarcinoma Pipeline Market Size by Country (2020-2025)
7.4 Europe Cholangiocarcinoma Pipeline Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cholangiocarcinoma Pipeline Market Size (2020-2031)
8.2 Asia-Pacific Cholangiocarcinoma Pipeline Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Cholangiocarcinoma Pipeline Market Size by Region (2020-2025)
8.4 Asia-Pacific Cholangiocarcinoma Pipeline Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cholangiocarcinoma Pipeline Market Size (2020-2031)
9.2 Latin America Cholangiocarcinoma Pipeline Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Cholangiocarcinoma Pipeline Market Size by Country (2020-2025)
9.4 Latin America Cholangiocarcinoma Pipeline Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cholangiocarcinoma Pipeline Market Size (2020-2031)
10.2 Middle East & Africa Cholangiocarcinoma Pipeline Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Cholangiocarcinoma Pipeline Market Size by Country (2020-2025)
10.4 Middle East & Africa Cholangiocarcinoma Pipeline Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Medivir
11.1.1 Medivir Company Details
11.1.2 Medivir Business Overview
11.1.3 Medivir Cholangiocarcinoma Pipeline Introduction
11.1.4 Medivir Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.1.5 Medivir Recent Development
11.2 Hutchison Medipharma
11.2.1 Hutchison Medipharma Company Details
11.2.2 Hutchison Medipharma Business Overview
11.2.3 Hutchison Medipharma Cholangiocarcinoma Pipeline Introduction
11.2.4 Hutchison Medipharma Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.2.5 Hutchison Medipharma Recent Development
11.3 Agios Pharmaceuticals
11.3.1 Agios Pharmaceuticals Company Details
11.3.2 Agios Pharmaceuticals Business Overview
11.3.3 Agios Pharmaceuticals Cholangiocarcinoma Pipeline Introduction
11.3.4 Agios Pharmaceuticals Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.3.5 Agios Pharmaceuticals Recent Development
11.4 TransThera Biosciences
11.4.1 TransThera Biosciences Company Details
11.4.2 TransThera Biosciences Business Overview
11.4.3 TransThera Biosciences Cholangiocarcinoma Pipeline Introduction
11.4.4 TransThera Biosciences Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.4.5 TransThera Biosciences Recent Development
11.5 Senhwa Biosciences
11.5.1 Senhwa Biosciences Company Details
11.5.2 Senhwa Biosciences Business Overview
11.5.3 Senhwa Biosciences Cholangiocarcinoma Pipeline Introduction
11.5.4 Senhwa Biosciences Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.5.5 Senhwa Biosciences Recent Development
11.6 Eisai
11.6.1 Eisai Company Details
11.6.2 Eisai Business Overview
11.6.3 Eisai Cholangiocarcinoma Pipeline Introduction
11.6.4 Eisai Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.6.5 Eisai Recent Development
11.7 EMD Serono
11.7.1 EMD Serono Company Details
11.7.2 EMD Serono Business Overview
11.7.3 EMD Serono Cholangiocarcinoma Pipeline Introduction
11.7.4 EMD Serono Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.7.5 EMD Serono Recent Development
11.8 Taiho Oncology
11.8.1 Taiho Oncology Company Details
11.8.2 Taiho Oncology Business Overview
11.8.3 Taiho Oncology Cholangiocarcinoma Pipeline Introduction
11.8.4 Taiho Oncology Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.8.5 Taiho Oncology Recent Development
11.9 Sirnaomics
11.9.1 Sirnaomics Company Details
11.9.2 Sirnaomics Business Overview
11.9.3 Sirnaomics Cholangiocarcinoma Pipeline Introduction
11.9.4 Sirnaomics Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.9.5 Sirnaomics Recent Development
11.10 RedHill Biopharma
11.10.1 RedHill Biopharma Company Details
11.10.2 RedHill Biopharma Business Overview
11.10.3 RedHill Biopharma Cholangiocarcinoma Pipeline Introduction
11.10.4 RedHill Biopharma Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.10.5 RedHill Biopharma Recent Development
11.11 MacroGenics
11.11.1 MacroGenics Company Details
11.11.2 MacroGenics Business Overview
11.11.3 MacroGenics Cholangiocarcinoma Pipeline Introduction
11.11.4 MacroGenics Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.11.5 MacroGenics Recent Development
11.12 Chia Tai Tianqing Pharmaceutical Group
11.12.1 Chia Tai Tianqing Pharmaceutical Group Company Details
11.12.2 Chia Tai Tianqing Pharmaceutical Group Business Overview
11.12.3 Chia Tai Tianqing Pharmaceutical Group Cholangiocarcinoma Pipeline Introduction
11.12.4 Chia Tai Tianqing Pharmaceutical Group Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.12.5 Chia Tai Tianqing Pharmaceutical Group Recent Development
11.13 Sirtex Medical
11.13.1 Sirtex Medical Company Details
11.13.2 Sirtex Medical Business Overview
11.13.3 Sirtex Medical Cholangiocarcinoma Pipeline Introduction
11.13.4 Sirtex Medical Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.13.5 Sirtex Medical Recent Development
11.14 Delcath Systems Inc.
11.14.1 Delcath Systems Inc. Company Details
11.14.2 Delcath Systems Inc. Business Overview
11.14.3 Delcath Systems Inc. Cholangiocarcinoma Pipeline Introduction
11.14.4 Delcath Systems Inc. Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.14.5 Delcath Systems Inc. Recent Development
11.15 Innovent Biologics
11.15.1 Innovent Biologics Company Details
11.15.2 Innovent Biologics Business Overview
11.15.3 Innovent Biologics Cholangiocarcinoma Pipeline Introduction
11.15.4 Innovent Biologics Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.15.5 Innovent Biologics Recent Development
11.16 PCI Biotech AS
11.16.1 PCI Biotech AS Company Details
11.16.2 PCI Biotech AS Business Overview
11.16.3 PCI Biotech AS Cholangiocarcinoma Pipeline Introduction
11.16.4 PCI Biotech AS Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.16.5 PCI Biotech AS Recent Development
11.17 Basilea Pharmaceutica
11.17.1 Basilea Pharmaceutica Company Details
11.17.2 Basilea Pharmaceutica Business Overview
11.17.3 Basilea Pharmaceutica Cholangiocarcinoma Pipeline Introduction
11.17.4 Basilea Pharmaceutica Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.17.5 Basilea Pharmaceutica Recent Development
11.18 QED Therapeutics
11.18.1 QED Therapeutics Company Details
11.18.2 QED Therapeutics Business Overview
11.18.3 QED Therapeutics Cholangiocarcinoma Pipeline Introduction
11.18.4 QED Therapeutics Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.18.5 QED Therapeutics Recent Development
11.19 Bristol-Myers Squibb
11.19.1 Bristol-Myers Squibb Company Details
11.19.2 Bristol-Myers Squibb Business Overview
11.19.3 Bristol-Myers Squibb Cholangiocarcinoma Pipeline Introduction
11.19.4 Bristol-Myers Squibb Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.19.5 Bristol-Myers Squibb Recent Development
11.20 AstraZeneca
11.20.1 AstraZeneca Company Details
11.20.2 AstraZeneca Business Overview
11.20.3 AstraZeneca Cholangiocarcinoma Pipeline Introduction
11.20.4 AstraZeneca Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.20.5 AstraZeneca Recent Development
11.21 Eli Lilly and Company
11.21.1 Eli Lilly and Company Company Details
11.21.2 Eli Lilly and Company Business Overview
11.21.3 Eli Lilly and Company Cholangiocarcinoma Pipeline Introduction
11.21.4 Eli Lilly and Company Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.21.5 Eli Lilly and Company Recent Development
11.22 Toray Industries
11.22.1 Toray Industries Company Details
11.22.2 Toray Industries Business Overview
11.22.3 Toray Industries Cholangiocarcinoma Pipeline Introduction
11.22.4 Toray Industries Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.22.5 Toray Industries Recent Development
11.23 Bold Therapeutics
11.23.1 Bold Therapeutics Company Details
11.23.2 Bold Therapeutics Business Overview
11.23.3 Bold Therapeutics Cholangiocarcinoma Pipeline Introduction
11.23.4 Bold Therapeutics Revenue in Cholangiocarcinoma Pipeline Business (2020-2025)
11.23.5 Bold Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Cholangiocarcinoma Pipeline Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Mono
Table 3. Key Players of Combination
Table 4. Global Cholangiocarcinoma Pipeline Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Cholangiocarcinoma Pipeline Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Cholangiocarcinoma Pipeline Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Cholangiocarcinoma Pipeline Market Share by Region (2020-2025)
Table 8. Global Cholangiocarcinoma Pipeline Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Cholangiocarcinoma Pipeline Market Share by Region (2026-2031)
Table 10. Cholangiocarcinoma Pipeline Market Trends
Table 11. Cholangiocarcinoma Pipeline Market Drivers
Table 12. Cholangiocarcinoma Pipeline Market Challenges
Table 13. Cholangiocarcinoma Pipeline Market Restraints
Table 14. Global Cholangiocarcinoma Pipeline Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Cholangiocarcinoma Pipeline Market Share by Players (2020-2025)
Table 16. Global Top Cholangiocarcinoma Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cholangiocarcinoma Pipeline as of 2024)
Table 17. Ranking of Global Top Cholangiocarcinoma Pipeline Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Cholangiocarcinoma Pipeline Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Cholangiocarcinoma Pipeline, Headquarters and Area Served
Table 20. Global Key Players of Cholangiocarcinoma Pipeline, Product and Application
Table 21. Global Key Players of Cholangiocarcinoma Pipeline, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Cholangiocarcinoma Pipeline Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Cholangiocarcinoma Pipeline Revenue Market Share by Type (2020-2025)
Table 25. Global Cholangiocarcinoma Pipeline Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Cholangiocarcinoma Pipeline Revenue Market Share by Type (2026-2031)
Table 27. Global Cholangiocarcinoma Pipeline Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Cholangiocarcinoma Pipeline Revenue Market Share by Application (2020-2025)
Table 29. Global Cholangiocarcinoma Pipeline Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Cholangiocarcinoma Pipeline Revenue Market Share by Application (2026-2031)
Table 31. North America Cholangiocarcinoma Pipeline Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Cholangiocarcinoma Pipeline Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Cholangiocarcinoma Pipeline Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Cholangiocarcinoma Pipeline Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Cholangiocarcinoma Pipeline Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Cholangiocarcinoma Pipeline Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Cholangiocarcinoma Pipeline Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Cholangiocarcinoma Pipeline Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Cholangiocarcinoma Pipeline Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Cholangiocarcinoma Pipeline Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Cholangiocarcinoma Pipeline Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Cholangiocarcinoma Pipeline Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Cholangiocarcinoma Pipeline Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Cholangiocarcinoma Pipeline Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Cholangiocarcinoma Pipeline Market Size by Country (2026-2031) & (US$ Million)
Table 46. Medivir Company Details
Table 47. Medivir Business Overview
Table 48. Medivir Cholangiocarcinoma Pipeline Product
Table 49. Medivir Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 50. Medivir Recent Development
Table 51. Hutchison Medipharma Company Details
Table 52. Hutchison Medipharma Business Overview
Table 53. Hutchison Medipharma Cholangiocarcinoma Pipeline Product
Table 54. Hutchison Medipharma Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 55. Hutchison Medipharma Recent Development
Table 56. Agios Pharmaceuticals Company Details
Table 57. Agios Pharmaceuticals Business Overview
Table 58. Agios Pharmaceuticals Cholangiocarcinoma Pipeline Product
Table 59. Agios Pharmaceuticals Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 60. Agios Pharmaceuticals Recent Development
Table 61. TransThera Biosciences Company Details
Table 62. TransThera Biosciences Business Overview
Table 63. TransThera Biosciences Cholangiocarcinoma Pipeline Product
Table 64. TransThera Biosciences Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 65. TransThera Biosciences Recent Development
Table 66. Senhwa Biosciences Company Details
Table 67. Senhwa Biosciences Business Overview
Table 68. Senhwa Biosciences Cholangiocarcinoma Pipeline Product
Table 69. Senhwa Biosciences Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 70. Senhwa Biosciences Recent Development
Table 71. Eisai Company Details
Table 72. Eisai Business Overview
Table 73. Eisai Cholangiocarcinoma Pipeline Product
Table 74. Eisai Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 75. Eisai Recent Development
Table 76. EMD Serono Company Details
Table 77. EMD Serono Business Overview
Table 78. EMD Serono Cholangiocarcinoma Pipeline Product
Table 79. EMD Serono Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 80. EMD Serono Recent Development
Table 81. Taiho Oncology Company Details
Table 82. Taiho Oncology Business Overview
Table 83. Taiho Oncology Cholangiocarcinoma Pipeline Product
Table 84. Taiho Oncology Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 85. Taiho Oncology Recent Development
Table 86. Sirnaomics Company Details
Table 87. Sirnaomics Business Overview
Table 88. Sirnaomics Cholangiocarcinoma Pipeline Product
Table 89. Sirnaomics Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 90. Sirnaomics Recent Development
Table 91. RedHill Biopharma Company Details
Table 92. RedHill Biopharma Business Overview
Table 93. RedHill Biopharma Cholangiocarcinoma Pipeline Product
Table 94. RedHill Biopharma Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 95. RedHill Biopharma Recent Development
Table 96. MacroGenics Company Details
Table 97. MacroGenics Business Overview
Table 98. MacroGenics Cholangiocarcinoma Pipeline Product
Table 99. MacroGenics Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 100. MacroGenics Recent Development
Table 101. Chia Tai Tianqing Pharmaceutical Group Company Details
Table 102. Chia Tai Tianqing Pharmaceutical Group Business Overview
Table 103. Chia Tai Tianqing Pharmaceutical Group Cholangiocarcinoma Pipeline Product
Table 104. Chia Tai Tianqing Pharmaceutical Group Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 105. Chia Tai Tianqing Pharmaceutical Group Recent Development
Table 106. Sirtex Medical Company Details
Table 107. Sirtex Medical Business Overview
Table 108. Sirtex Medical Cholangiocarcinoma Pipeline Product
Table 109. Sirtex Medical Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 110. Sirtex Medical Recent Development
Table 111. Delcath Systems Inc. Company Details
Table 112. Delcath Systems Inc. Business Overview
Table 113. Delcath Systems Inc. Cholangiocarcinoma Pipeline Product
Table 114. Delcath Systems Inc. Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 115. Delcath Systems Inc. Recent Development
Table 116. Innovent Biologics Company Details
Table 117. Innovent Biologics Business Overview
Table 118. Innovent Biologics Cholangiocarcinoma Pipeline Product
Table 119. Innovent Biologics Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 120. Innovent Biologics Recent Development
Table 121. PCI Biotech AS Company Details
Table 122. PCI Biotech AS Business Overview
Table 123. PCI Biotech AS Cholangiocarcinoma Pipeline Product
Table 124. PCI Biotech AS Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 125. PCI Biotech AS Recent Development
Table 126. Basilea Pharmaceutica Company Details
Table 127. Basilea Pharmaceutica Business Overview
Table 128. Basilea Pharmaceutica Cholangiocarcinoma Pipeline Product
Table 129. Basilea Pharmaceutica Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 130. Basilea Pharmaceutica Recent Development
Table 131. QED Therapeutics Company Details
Table 132. QED Therapeutics Business Overview
Table 133. QED Therapeutics Cholangiocarcinoma Pipeline Product
Table 134. QED Therapeutics Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 135. QED Therapeutics Recent Development
Table 136. Bristol-Myers Squibb Company Details
Table 137. Bristol-Myers Squibb Business Overview
Table 138. Bristol-Myers Squibb Cholangiocarcinoma Pipeline Product
Table 139. Bristol-Myers Squibb Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 140. Bristol-Myers Squibb Recent Development
Table 141. AstraZeneca Company Details
Table 142. AstraZeneca Business Overview
Table 143. AstraZeneca Cholangiocarcinoma Pipeline Product
Table 144. AstraZeneca Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 145. AstraZeneca Recent Development
Table 146. Eli Lilly and Company Company Details
Table 147. Eli Lilly and Company Business Overview
Table 148. Eli Lilly and Company Cholangiocarcinoma Pipeline Product
Table 149. Eli Lilly and Company Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 150. Eli Lilly and Company Recent Development
Table 151. Toray Industries Company Details
Table 152. Toray Industries Business Overview
Table 153. Toray Industries Cholangiocarcinoma Pipeline Product
Table 154. Toray Industries Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 155. Toray Industries Recent Development
Table 156. Bold Therapeutics Company Details
Table 157. Bold Therapeutics Business Overview
Table 158. Bold Therapeutics Cholangiocarcinoma Pipeline Product
Table 159. Bold Therapeutics Revenue in Cholangiocarcinoma Pipeline Business (2020-2025) & (US$ Million)
Table 160. Bold Therapeutics Recent Development
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
Table 164. Authors List of This Report


List of Figures
Figure 1. Cholangiocarcinoma Pipeline Picture
Figure 2. Global Cholangiocarcinoma Pipeline Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Cholangiocarcinoma Pipeline Market Share by Type: 2024 VS 2031
Figure 4. Mono Features
Figure 5. Combination Features
Figure 6. Global Cholangiocarcinoma Pipeline Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Cholangiocarcinoma Pipeline Market Share by Application: 2024 VS 2031
Figure 8. Gene Therapy Case Studies
Figure 9. Stem Cell Therapy Case Studies
Figure 10. Gene Therapy Case Studies
Figure 11. Cholangiocarcinoma Pipeline Report Years Considered
Figure 12. Global Cholangiocarcinoma Pipeline Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Cholangiocarcinoma Pipeline Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Cholangiocarcinoma Pipeline Market Share by Region: 2024 VS 2031
Figure 15. Global Cholangiocarcinoma Pipeline Market Share by Players in 2024
Figure 16. Global Top Cholangiocarcinoma Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cholangiocarcinoma Pipeline as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Cholangiocarcinoma Pipeline Revenue in 2024
Figure 18. North America Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Cholangiocarcinoma Pipeline Market Share by Country (2020-2031)
Figure 20. United States Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Cholangiocarcinoma Pipeline Market Share by Country (2020-2031)
Figure 24. Germany Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Cholangiocarcinoma Pipeline Market Share by Region (2020-2031)
Figure 32. China Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Cholangiocarcinoma Pipeline Market Share by Country (2020-2031)
Figure 40. Mexico Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Cholangiocarcinoma Pipeline Market Share by Country (2020-2031)
Figure 44. Turkey Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Cholangiocarcinoma Pipeline Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Medivir Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 48. Hutchison Medipharma Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 49. Agios Pharmaceuticals Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 50. TransThera Biosciences Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 51. Senhwa Biosciences Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 52. Eisai Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 53. EMD Serono Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 54. Taiho Oncology Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 55. Sirnaomics Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 56. RedHill Biopharma Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 57. MacroGenics Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 58. Chia Tai Tianqing Pharmaceutical Group Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 59. Sirtex Medical Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 60. Delcath Systems Inc. Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 61. Innovent Biologics Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 62. PCI Biotech AS Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 63. Basilea Pharmaceutica Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 64. QED Therapeutics Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 65. Bristol-Myers Squibb Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 66. AstraZeneca Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 67. Eli Lilly and Company Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 68. Toray Industries Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 69. Bold Therapeutics Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2020-2025)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies